Department of Medicine, University of Granada, Granada, Spain.
Instituto de Investigación Biosanitaria de Granada, Granada, Spain.
Front Endocrinol (Lausanne). 2022 Apr 14;13:863940. doi: 10.3389/fendo.2022.863940. eCollection 2022.
Hypophosphatasia (HPP) a rare disease caused by mutations in the gene encoding for the tissue-nonspecific alkaline phosphatase protein (TNSALP), has been identified as a potentially under-diagnosed condition worldwide which may have higher prevalence than currently established. This is largely due to the overlapping of its symptomatology with that of other more frequent pathologies. Although HPP is usually associated with deficient bone mineralization, the high genetic variability of results in high clinical heterogeneity, which makes it difficult to establish a specific HPP symptomatology. In the present study, three variants of gene with uncertain significance and no previously described (p.Del Glu23_Lys24, p.Pro292Leu and p.His379Asn) were identified in heterozygosis in patients diagnosed with HPP. These variants were characterized at phenotypic, functional and structural levels. All genetic variants showed significantly lower ALP activity than the wild-type (WT) genotype (-value <0.001). Structurally, p.His379Asn variant resulted in the loss of two Zn binding sites in the protein dimer which may greatly affect ALP activity. In summary, we identified three novel gene mutations associated with adult HPP. The correct identification and characterization of new variants and the subsequent study of their phenotype will allow the establishment of genotype-phenotype relationships that facilitate the management of the disease as well as making it possible to individualize treatment for each specific patient. This would allow the therapeutic approach to HPP to be personalized according to the unique genetic characteristics and clinical manifestations of each patient.
低磷酸酯酶症(HPP)是一种由组织非特异性碱性磷酸酶蛋白(TNSALP)基因编码突变引起的罕见疾病,已被确定为一种在全球范围内可能被低估的潜在疾病,其患病率可能高于目前已确定的水平。这主要是由于其症状与其他更常见的疾病重叠。尽管 HPP 通常与骨矿化不足有关,但 基因的高度遗传变异性导致了高度的临床异质性,这使得难以建立特定的 HPP 症状。在本研究中,在诊断为 HPP 的患者中发现了三种具有不确定意义且以前未描述过的 基因变体(p.Del Glu23_Lys24、p.Pro292Leu 和 p.His379Asn)杂合。这些变体在表型、功能和结构水平上进行了特征描述。所有遗传变体的 ALP 活性均明显低于野生型(WT)基因型(-值<0.001)。结构上,p.His379Asn 变体导致蛋白质二聚体中失去了两个 Zn 结合位点,这可能极大地影响 ALP 活性。总之,我们鉴定了三种与成人 HPP 相关的新的 基因突变。正确识别和表征新变体,并随后研究其表型,将有助于建立基因型-表型关系,从而便于疾病的管理,并使对每个特定患者的个体化治疗成为可能。这将使 HPP 的治疗方法能够根据每个患者独特的遗传特征和临床表现进行个体化。